TW202330596A - 經修飾的蛋白或多肽 - Google Patents

經修飾的蛋白或多肽 Download PDF

Info

Publication number
TW202330596A
TW202330596A TW111145700A TW111145700A TW202330596A TW 202330596 A TW202330596 A TW 202330596A TW 111145700 A TW111145700 A TW 111145700A TW 111145700 A TW111145700 A TW 111145700A TW 202330596 A TW202330596 A TW 202330596A
Authority
TW
Taiwan
Prior art keywords
single variable
variable domain
immunoglobulin single
seq
amino acid
Prior art date
Application number
TW111145700A
Other languages
English (en)
Chinese (zh)
Inventor
王楠
楊曉峰
張偉
曹志亮
葉浩
沈余紅
廖成
Original Assignee
大陸商江蘇恆瑞醫藥股份有限公司
大陸商上海盛迪醫藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商江蘇恆瑞醫藥股份有限公司, 大陸商上海盛迪醫藥有限公司 filed Critical 大陸商江蘇恆瑞醫藥股份有限公司
Publication of TW202330596A publication Critical patent/TW202330596A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW111145700A 2021-11-29 2022-11-29 經修飾的蛋白或多肽 TW202330596A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111429892.3 2021-11-29
CN202111429892 2021-11-29

Publications (1)

Publication Number Publication Date
TW202330596A true TW202330596A (zh) 2023-08-01

Family

ID=86538884

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111145700A TW202330596A (zh) 2021-11-29 2022-11-29 經修飾的蛋白或多肽

Country Status (6)

Country Link
US (1) US20250026842A1 (https=)
EP (1) EP4435002A4 (https=)
JP (1) JP2024543134A (https=)
CN (1) CN118339179A (https=)
TW (1) TW202330596A (https=)
WO (1) WO2023093899A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024114676A1 (zh) 2022-11-29 2024-06-06 江苏恒瑞医药股份有限公司 Cldn18.2/4-1bb结合蛋白及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
SG10201805064SA (en) * 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
RS55775B2 (sr) * 2011-06-23 2022-10-31 Ablynx Nv Tehnike za predviđanje, otkrivanje i smanjenje nespecifične proteinske interferencije u testovima koji uključuju pojedinačne varijabilne domene imunoglobulina
PE20141522A1 (es) 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
AU2013258834B2 (en) * 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
WO2014111550A1 (en) * 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
EP4707303A2 (en) * 2014-05-16 2026-03-11 Ablynx NV Improved immunoglobulin variable domains
JP7001474B2 (ja) * 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
NO2768984T3 (https=) * 2015-11-12 2018-06-09
CN113621065B (zh) * 2021-08-30 2023-08-01 武汉海沙百得生物技术有限公司 靶向4-1bb的全人源抗体及其制备方法和应用

Also Published As

Publication number Publication date
WO2023093899A1 (zh) 2023-06-01
US20250026842A1 (en) 2025-01-23
JP2024543134A (ja) 2024-11-19
EP4435002A1 (en) 2024-09-25
CN118339179A (zh) 2024-07-12
EP4435002A4 (en) 2025-03-26

Similar Documents

Publication Publication Date Title
JP7264827B2 (ja) ＴＧＦ－β受容体含有融合タンパク質およびそれらの医薬的用途
TW202126694A (zh) 標靶cd3的抗體、雙特異性抗體及其用途
EP3744734A1 (en) Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof
EP3632932A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
EP4393950A1 (en) Fap/cd40 binding molecule and medicinal use thereof
US20240124563A1 (en) Anti-Human MSLN Antibody And Application Thereof
EP4674868A1 (en) Fap/4-1bb/cd40 binding molecule and medicinal use thereof
KR20210121102A (ko) 항-cd79b 항체, 이의 항원-결합 단편, 및 이의 약학적 용도
CA3231320A1 (en) Protein specifically binding to pd-1 and pharmaceutical use thereof
EP4377358A1 (en) Novel anti-sirpa antibodies
TW202421667A (zh) Ｃｌｄｎ１８．２／４－１ｂｂ結合蛋白及其醫藥用途
CN118108853A (zh) Cd47/4-1bb结合蛋白及其医药用途
US20250026842A1 (en) Modified protein or polypeptide
EP4671282A1 (en) IL-36R BINDING PROTEIN AND ITS MEDICINAL USE
CN116813786B (zh) 抗cd73抗体及其应用
TW202537974A (zh) Ｔｒｇｖ９結合蛋白及其醫藥用途
WO2025195358A1 (zh) Pd-1结合蛋白及医药用途
CA3284183A1 (en) Fap/4-1bb/cd40 binding molecule and medicinal use thereof
HK40106257A (zh) 新型抗sirpa抗体
KR20200119846A (ko) 항 비7 에이치4 항체, 그의 항원 결합 단편 및 그의 약학적 용도